PPARA and metabolic syndrome: Dysregulation of lipoprotein lipase (LPL) contributes to dyslipidemia, and LPL inducers, such as PPAR ligands, NO-1886, and indomethacin, have been shown to decrease TG levels and suppress tumor development in animal models [60].